Abstract:BackgroundPeriprosthetic osteolysis is a major cause of aseptic loosening in joint arthroplasty. This study investigates the impact of CT (calcitonin) deficiency and CT substitution under in-vivo circumstances on particle-induced osteolysis in Calca -/- mice.MethodsWe used the murine calvarial osteolysis model based on ultra-high molecular weight polyethylene (UHMWPE) particles in 10 C57BL/6J wild-type (WT) mice and twenty Calca -/- mice. The mice were divided into six groups: WT without UHMWPE particles (Grou… Show more
“…However we found no effect of LIR on calcitonin secretion while studies have reported that both Ex-4 and LIR stimulate calcitonin secretion (63,64). Our data are not completely consistent with this mechanism since we observed an increase in resorption surfaces with GLP-1 agonists whereas other studies have reported that calcitonin decreased resorption surfaces (65).…”
“…However we found no effect of LIR on calcitonin secretion while studies have reported that both Ex-4 and LIR stimulate calcitonin secretion (63,64). Our data are not completely consistent with this mechanism since we observed an increase in resorption surfaces with GLP-1 agonists whereas other studies have reported that calcitonin decreased resorption surfaces (65).…”
“…However, the observed reduction in PIO in a-CGRP-deficient mice could have been attributed to a compensatory effect of CT. Huebner et al [16] reported the dual action of CT, as an inhibitor of both bone formation and bone resorption, which could be highly relevant in conditions associated with increased bone resorption, such as PIO. Therefore, further investigations on Calca À/À mice with a combined deficiency in a-CGRP and CT were performed and showed pronounced osteolysis in UHMWPE particle-treated mice at the age of 3 months, while additional substitution of CT in these animals revealed a reduction in PIO [11]. Thus, activation of the CTR could play a crucial role in the PIO process.…”
Section: Introductionmentioning
confidence: 92%
“…In the presence of UHMWPE particles, a reduced http://dx.doi.org/10.1016/j.actbio.2014. 11.051 1742-7061/Ó 2014 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.…”
Section: Introductionmentioning
confidence: 96%
“…In an attempt to assess the impact of CT/a-CGRP in the presence of UHMWPE particles, mice with an isolated or combined deficiency of a-CGRP and CT were studied [11][12][13]. While UHMWPE particles revealed pronounced osteolysis in wild-type mice, different observations in a-CGRP-and CT-deficient mice were made [14].…”
“…Addition of other agents, including berberine, captropril, dynastat, and N-acetyl-L-cysteine, decreased particle-dependent inflammation and associated osteolysis [14,16,60,61]. In studies taking advantage of knockout mutations, protein replacement of calcitonin and IL-6 increased bone and decreased inflammation, respectively, in calcitonin-negative and IL-6-negative animals [11,19]. The mouse model of osteolysis also allowed agents to be tested locally at the site of the applied particles.…”
Where Are We Now? Biological treatments, defined as any nonsurgical intervention whose primary mechanism of action is reducing the host response to wear and/or corrosion products, have long been postulated as solutions for osteolysis and aseptic loosening of total joint arthroplasties. Despite extensive research on drugs that target the inflammatory, osteoclastic, and osteogenic responses to wear debris, no biological treatment has emerged as an approved therapy. We review the extensive preclinical research and modest clinical research to date, which has led to the central conclusion that the osteoclast is the primary target. We also allude to the significant changes in health care, unabated safety concerns about chronic immunosuppressive/antiinflammatory therapies, industry's complete lack of interest in developing an intervention for this condition, and the practical issues that have narrowly focused the possibilities for a biologic treatment for wear debris-induced osteolysis. Where Do We Need to Go? Based on the conclusions from research, and the economic, regulatory, and practical issues that limit the future directions toward the development of a biologic treatment, there are a few rational approaches that warrant investigation. These largely focus on FDA-approved osteoporosis therapies that target the osteoclast (bisphosphonates and anti-RANK ligand) and recombinant parathyroid hormone (teriparatide) prophylactic treatment to increase osseous integration of the prosthesis to overcome high-risk susceptibility to aseptic loosening. The other roadblock that must be overcome if there is to be an approved biologic therapy to prevent the progression of periprosthetic osteolysis and aseptic loosening is the development of radiological measures that can quantify a significant drug effect in a randomized, placebocontrolled clinical trial. We review the progress of volumetric quantification of osteolysis in animal studies and clinical pilots. How Do We Get There? Accepting the aforementioned rigid boundaries, we describe the emergence of repurposing FDA-approved drugs for new indications and public (National Institutes of Health, FDA, Centers for Disease Control and Prevention) and private (universities and drug and device manufactures) partnerships as the future roadmap for clinical translation. In the case of biologic treatments for wear debris-induced osteolysis, this will
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.